Senior Equity Analyst
Since its founding in 2010, Kancera has worked with the development of small molecule drug candidates for inflammatory diseases and cancer. The company conducts clinical development in myocardial infarction.
|Initiation of coverage:||24 October 2022|
|List:||Nasdaq First North|